TherapeuticsMD (TXMD) Misses Q2 EPS by 17c

TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.24), $0.17 worse than the analyst estimate of ($0.07).

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'